OCT 17 2005 Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

sperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known SUB-Substitut **Application Number**

10/077,111 **Filing Date** INFORMATION DISCLOSURE 02/15/2002 STATEMENT BY APPLICANT **First Named Inventor CHARLES TODDERUD** Art Unit 1635 (Use as many sheets as necessary)

PTO/SB/08B (08-03)

Examiner Name ZARA, JANE J Attorney Docket Number Sheet D0031 NP of NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
93		Database Geneseq, No. AAI58876, Novel Nucleic Acids and Polypeptides, Useful for Treating Disorders Such as Central Nervous System Injuries, Tang, et al. 26 July 2001.	
		·	
		·	
·			

Examiner Signature	72 -	Date Considered	11-27-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with pext communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Applicant's unique ciasion designation in imper (opionas). Applicant is to piace a crieck mark nere it english language i ranslation is structed. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.